We are live on
!
Find out more
Madrigal Pharmaceuticals
MDGL
MDGL
53 hedge funds and large institutions have $120M invested in Madrigal Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
261% more capital invested
Capital invested by funds: $33.3M → $120M (+$87M)
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
26% more funds holding
Funds holding: 42 → 53 (+11)
4.56% more ownership
Funds ownership: 16.82% → 21.39% (+4.6%)
Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
15
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.4M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$1.87M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$1.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 5 |
Renaissance Technologies
New York
|
+$971K |
Top Sellers
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.96M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.87M |
| 3 |
AC
Armistice Capital
New York
|
-$1.31M |
| 4 |
Citigroup
New York
|
-$185K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$64K |
